AI in biotech: separating hype from reality with Ben Locwin

About this episode

The episode discusses the role of AI in biotechnology, highlighting the gap between claims and reality, with insights from expert Ben Locwin.

In this episode of Data in Biotech, host Ross Katz sits down with Ben Locwin, Vice President at Reliant Life Sciences, to explore the evolving landscape of artificial intelligence in biotechnology. Join us as we discuss why nearly every biotech claims to use AI but few actually do, examine successful applications like AlphaFold, and explore the challenges of implementing AI across drug development, manufacturing, and regulatory processes. Ben shares insights on maintaining healthy skepticism, understanding data provenance, and looking ahead to what this year may bring for AI in life sciences. What you’ll learn in this episode: >> The AI hype problem in biotech and why most companies claim to use AI but few actually do. >> AlphaFold as the gold standard and how DeepMind's protein structure prediction model represents the most successful application of AI in biotech >> Data quality over algorithmic sophistication and the critical importance of data provenance, examining primary sources, and understanding that data quality matters more than the complexity of the AI model >> The balance between optimism and evidence-based decision-making, distinguishing…

People in this episode

Host: Ross Katz

Guest: Ben Locwin

Topics covered

• artificial intelligence
• biotechnology
• drug development
• data quality
• regulatory processes
• skepticism in biotech

Keywords

• AI in biotech
• data provenance
• AlphaFold
• drug development
• biotech challenges
• evidence-based decision-making

Mentioned in this episode

Organizations: Reliant Life Sciences, DeepMind

Products: AlphaFold

More episodes of Data in Biotech

• From Tissue to Mechanism to Decision: Building AI for Computational Oncology · June 2, 2026 · 47 min
• Cavities in the Data: Building FDA-Cleared AI for Dental Imaging with Overjet · May 13, 2026 · 59 min
• Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive · April 30, 2026 · 43 min
• Markus Gershater on Why Experimental Design in Biotech is Broken and How to Fix It · April 15, 2026 · 41 min
• Data Science and Diagnostic Models - the What, Why and How with Michelle Wiest · April 15, 2026 · 44 min
• The Patient is Not a Document: Foundation Models for Biomedical AI with Standard BioModel · April 15, 2026 · 50 min